Evidence map›Paper›PMID 12384350›Full record

ArticleAntimicrobial agents and chemotherapy2002

Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2).

Gregory C Williams, Angela Liu, Gregory Knipp, Patrick J Sinko

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 121 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Drug resistance: from bacteria to cancer.Molecular biomedicine · 2021
    Review
  5. Renal Drug Transporters and Drug Interactions.Clinical pharmacokinetics · 2017
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Prodrug and conjugate drug delivery strategies for improving HIV/AIDS therapy.Journal of drug delivery science and technology · 2009
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Gregory C WilliamsDepartment of Pharmaceutics, School of Pharmacy, Rutgers University, Piscataway, New Jersey 08854, USA.
Angela Liu
Gregory Knipp
Patrick J Sinko
Johnson University · US

Funding

ORAL BIOAVAILABILITY AND VARIABILITY OF ANTIAIDS DRUGSR01AI042007 · NIAID · RUTGERS THE ST UNIV OF NJ NEW BRUNSWICK · PI SINKO, PATRICK J. · 1998 to 2000
$145k
ORAL BIOAVAILABILITY AND VARIABILITY OF ANTIAIDS DRUGSR21AI042007 · NIAID · RUTGERS THE ST UNIV OF NJ NEW BRUNSWICK · PI SINKO, PATRICK J. · 1997 to 1997
–
NIAID NIH HHS AI 42007
6 · The paper itself

Abstract

To determine if saquinavir mesylate (saquinavir) is a substrate of human multidrug resistance-associated protein 1 (hMRP1 [ABCC1]) or hMRP2 (cMOAT, or ABCC2), MDCKII cells that overexpress either hMRP1 (MDCKII-MRP1) or hMRP2 (MDCKII-MRP2) were used to investigate saquinavir's cytotoxicity and transport in comparison with those of control MDCKII wild-type (MDCKII/wt) cells. Cytotoxicity was assessed with the mitochondrial marker MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium], and saquinavir transport was measured directly through the cell monolayers. GF120918 (an inhibitor of P glycoprotein, but not of the MRP family) and MK-571 (an MRP family inhibitor) were used to delineate the specific contributions of these transporters to saquinavir cytotoxicity and transport. In the presence of GF120918 and increasing saquinavir concentrations, the MDCKII-MRP1 (50% lethal dose [LD(50)] = 10.5 micro M) and MDCKII-MRP2 (LD(50) = 27.1 micro M) cell lines exhibited statistically greater viability than the MDCKII/wt cells (LD(50) = 7.8 micro M). Saquinavir efflux was directional, not saturable, and was inhibited by MK-571 (35 and 75 micro M) in all cell lines. The ratios of saquinavir (3 micro M) basolateral to apical permeability (i.e., efflux ratios) for the MDCKII/wt, MDCKII-MRP1, and MDCKII-MRP2 cell monolayers were 2.6, 1.8, and 6.8, respectively. The MDCKII-MRP1 cells have a significantly reduced saquinavir efflux ratio relative to MDCKII/wt cells, due to basolaterally directed transport by hMRP1 competing with endogenous, apically directed canine MRP2. The MDCKII-MRP2 cells have a significantly increased saquinavir efflux ratio relative to MDCKII/wt cells, due to the additive effects of the apically directed transport by hMRP2 and endogenous MRP2. Collectively, the cytotoxicity and transport results provide direct evidence that saquinavir is transported by MRP1 and MRP2.

Indexed as

Mitochondrial ProteinsSaccharomyces cerevisiae ProteinsTetrahydroisoquinolinesAcridinesAlgorithmsAnimalsAnti-HIV AgentsATP-Binding Cassette, Sub-Family C ProteinsATP Binding Cassette Transporter, Subfamily BBiological AvailabilityBiological Transport, ActiveCell LineDogsHumansIsoquinolinesMolecular WeightABCC2 protein, humanAcridinesAnti-HIV AgentsATP-Binding Cassette, Sub-Family C ProteinsATP Binding Cassette Transporter, Subfamily BElacridarIsoquinolinesMitochondrial ProteinsMRP2 protein, S cerevisiaemultidrug resistance-associated protein 1Multidrug Resistance-Associated Protein 2PropionatesQuinolinesRibosomal ProteinsSaccharomyces cerevisiae ProteinsSaquinavirTetrahydroisoquinolinesverlukast

Identifiers

PMID12384350
PMCPMC128726
OpenAlexW2160246216

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.